Australia · Delayed Price · Currency is AUD Arovella Therapeutics Company Description
Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer in Australia and internationally.
The company product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and lung and ovarian cancer; and IL-12-TM for treating solid tumors.
Its ALA-101 product entered first-in-human phase 1 clinical trial. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021.
Arovella Therapeutics Limited was incorporated in 1999 and is based in Preston, Australia.
| Country | Australia |
| Founded | 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 27 |
| CEO | Michael Baker |
Contact Details
Address: Corporate One Preston, Western Australia 3072 Australia | |
| Phone | 61 3 9863 6472 |
| Website | arovella.com |
Stock Details
| Ticker Symbol | ALA |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU0000182784 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michael Baker | Chief Executive Officer, MD and Director |
| Dr. Nicole van der Weerden B.Sc., BSc (Hons), MBA (MBS), Ph.D. | Chief Operating Officer |
| Timothy Luscombe B.Com., C.A. | Company Secretary and Chief Financial Officer |
| Michelle Long | Administration Manager |